CLRB - Cellectar Biosciences, Inc.
2.75
-0.010 -0.364%
Share volume: 114,458
Last Updated: 03-09-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.20%
PREVIOUS CLOSE
CHG
CHG%
$2.76
-0.01
0.00%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 10-29-2024 | 10-29-2024 | 11-18-2024 | 03-13-2025 | 05-13-2025 | 08-14-2025 | 11-13-2025 | 03-04-2026 | |
| Assets | |||||||||
| Total Assets | 42.908 M | 29.385 M | 37.293 M | 25.474 M | 16.042 M | 13.695 M | 14.628 M | 14.978 M | |
| Current Assets | 41.368 M | 27.905 M | 35.899 M | 24.250 M | 14.893 M | 12.618 M | 13.622 M | 14.038 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 40.031 M | 25.869 M | 34.263 M | 23.289 M | 13.905 M | 11.041 M | 12.554 M | 13.196 M | |
| Total Non-current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Property Plant Equipment | 1.023 M | 978.701 K | 910.131 K | 757.121 K | 700.826 K | 647.549 K | 595.271 K | 549.405 K | |
| Other Assets | 516.627 K | 500.596 K | 483.946 K | 466.654 K | 448.696 K | 430.028 K | 410.621 K | 390.451 K | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 42.908 M | 29.385 M | 37.293 M | 25.474 M | 16.042 M | 13.695 M | 14.628 M | 14.978 M | |
| Total liabilities | 29.025 M | 15.622 M | 20.746 M | 9.797 M | 6.407 M | 6.228 M | 5.248 M | 5.059 M | |
| Total current liabilities | 28.551 M | 15.168 M | 20.314 M | 9.388 M | 6.021 M | 5.867 M | 4.912 M | 4.750 M | |
| Accounts Payable | 7.394 M | 6.463 M | 8.304 M | 7.585 M | 3.874 M | 4.679 M | 4.015 M | 4.424 M | |
| Other liabilities | 474.349 K | 453.508 K | 431.929 K | 409.586 K | 386.203 K | 361.487 K | 335.895 K | 309.397 K | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 474.349 K | 453.508 K | 431.929 K | 409.586 K | 386.203 K | 361.487 K | 335.895 K | 309.397 K | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | -4.567 M | 4.537 M | 1.549 M | 13.774 M | 7.733 M | 5.564 M | 7.477 M | 8.016 M | |
| Common stock | 224.836 M | 234.860 M | 246.536 M | 261.116 M | 261.679 M | 264.959 M | 271.315 M | 277.150 M | |
| Retained earnings | -229.403 M | -230.322 M | -244.987 M | -247.342 M | -253.946 M | -259.394 M | -263.838 M | -269.134 M |